DE69715000T2 - Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens - Google Patents

Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens

Info

Publication number
DE69715000T2
DE69715000T2 DE69715000T DE69715000T DE69715000T2 DE 69715000 T2 DE69715000 T2 DE 69715000T2 DE 69715000 T DE69715000 T DE 69715000T DE 69715000 T DE69715000 T DE 69715000T DE 69715000 T2 DE69715000 T2 DE 69715000T2
Authority
DE
Germany
Prior art keywords
csf
administration
recurrency
preventing
brain tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69715000T
Other languages
English (en)
Other versions
DE69715000D1 (de
Inventor
C Low
A Wallenfriedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota filed Critical University of Minnesota
Publication of DE69715000D1 publication Critical patent/DE69715000D1/de
Application granted granted Critical
Publication of DE69715000T2 publication Critical patent/DE69715000T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69715000T 1996-06-27 1997-06-18 Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens Expired - Lifetime DE69715000T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/671,251 US5837231A (en) 1996-06-27 1996-06-27 GM-CSF administration for the treatment and prevention of recurrence of brain tumors
PCT/US1997/010540 WO1997049421A1 (en) 1996-06-27 1997-06-18 Gm-csf administration for the treatment and prevention of recurrence of brain tumors

Publications (2)

Publication Number Publication Date
DE69715000D1 DE69715000D1 (de) 2002-10-02
DE69715000T2 true DE69715000T2 (de) 2003-01-02

Family

ID=24693739

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69715000T Expired - Lifetime DE69715000T2 (de) 1996-06-27 1997-06-18 Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens

Country Status (9)

Country Link
US (1) US5837231A (de)
EP (1) EP0912192B1 (de)
JP (1) JP2000515127A (de)
AT (1) ATE222769T1 (de)
AU (1) AU3400297A (de)
CA (1) CA2258608A1 (de)
DE (1) DE69715000T2 (de)
DK (1) DK0912192T3 (de)
WO (1) WO1997049421A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
WO1999029852A1 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
DE69940731D1 (de) * 1998-05-26 2009-05-28 Genitrix Llc Zusammensetzungen und verfahren zur modulation einer immunantwort auf ein antigen durch verabreichung von zytokine-beladenen zellen
AU5458500A (en) * 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
PT1326961E (pt) * 2000-09-15 2007-10-02 Ortho Mcneil Pharm Inc Composições e métodos para induzir respostas citolíticas específicas de células t
DE60231263D1 (de) * 2001-03-12 2009-04-02 Inst Of Gene And Brain Science Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20090155311A1 (en) * 2006-01-07 2009-06-18 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
WO2013072901A2 (en) * 2011-11-17 2013-05-23 Btm Mazowsze Sp. Zo.O. Compositions and methods for treating glioma
WO2013078392A1 (en) * 2011-11-21 2013-05-30 The University Of Chicago Methods and compositions involving induced senescent cells for cancer treatment
EP3711778B1 (de) 2011-12-02 2024-05-08 Armagen, Inc. Verfahren und zusammensetzungen für erhöhte sulfatase-a-aktivität im zns
PT3536334T (pt) 2012-05-16 2021-09-27 Stemline Therapeutics Inc Vacinas contra o cancro dirigidas a células estaminais cancerígenas
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5208022A (en) * 1988-05-19 1993-05-04 State University Of New York (Suny) Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
EP1216710B1 (de) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulierung der systemischen Immunantworten mittels Zytokinen und Antigenen

Also Published As

Publication number Publication date
EP0912192A1 (de) 1999-05-06
JP2000515127A (ja) 2000-11-14
ATE222769T1 (de) 2002-09-15
AU3400297A (en) 1998-01-14
US5837231A (en) 1998-11-17
DE69715000D1 (de) 2002-10-02
EP0912192B1 (de) 2002-08-28
CA2258608A1 (en) 1997-12-31
DK0912192T3 (da) 2002-12-02
WO1997049421A1 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
DE69715000D1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
FI933862A (fi) Loesliga ligander foer CD40
DE69703649T2 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69231294D1 (de) Vorrichtung zur behandlung von tumoren
DE69010893T2 (de) Verfahren zur behandlung von koks sowie löschen desselben.
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ATE77961T1 (de) Verfahren zur behandlung der unfruchtbarkeit und mittel zur verwendung dabei.
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE3574974D1 (de) Verfahren zur herstellung von milbemycinderivaten und einige in diesem verfahren verwendete derivate.
ATE288279T1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
UA22037A (uk) Спосіб лікуваhhя виразкової хвороби шлуhка та дваhадцятипалої кишки
DE58904510D1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.